aco/pharma commercial data analytics service models

CONFIDENTIAL Copyright 2014 Nintai Partners All Rights Reserved. Permission Required Before Duplication.

September 6th, 2013

Optimal Commercial Data and Analytics Service Models:

An Overview


Our Expertise

Pharmaceutical Data and Informatics Nintai Partners’ leadership has nearly a quarter century of experience working with pharmaceutical data and informatics. Working with everything from traditional IMS sales data, regulatory CDISC, evidence-based medicine data, and ACO-performance metrics, Nintai Partners provides the most comprehensive knowledge in the marketplace. Deep Understanding of Changes in Pharmaceuticals It isn’t just the breadth and depth of data changing the pharmaceutical world. These data sets are part of a tremendous change in the industry, ranging from drug discovery/development outsourcing, a transition from traditional sales to account-based selling models, and the increasing role of specialty drugs in pharmaceutical companies. portfolios. Putting It All Together Nintai Partners presents a truly innovative approach to creating executable solutions. No engagement is the same and we pride ourselves on unique, partner-driven solutions. We are not afraid to discuss finding and best practices from outside the industry, as well as providing unvarnished recommendations to our partners.


Data Services Solution: Core Strategic Drivers

No industry has survived by continually cutting their way to survival. The ultimate long term health of the industry will

be driven by sustainable and profitable growth. To achieve this, continued increases in productivity need to occur with

R&D in order to drive the IRR.

New relationships will need to be created – with incentives for both cost savings and corporate growth. These relationships will require more flexible

and integrated business models.

The industry has never been a leader in the use of informatics, technology, and integrated data

platforms. The increasing digitization of data at all levels (EDC, EMRs, eCTD) is going to

fundamentally change the way we make decisions.


Data Services Solution: Nintai Partners’ Evaluation Process

Strategic Need

Step 1

What is the strategic need of the data infrastructure?

Data Sources

Step 2

What currently makes up data source inventory?

Data Ownership

Step 3

Who currently owns/sponsors each data asset?

Data Update/ Validation

Step 4

How are these data sources updated and validated?

Data Access/ Rights

Step 5

Who has access to data and at what authority ?

Data Regulatory Needs

Step 6

What regulatory requirements are required for data?

Nintai Partners utilizes a proprietary six (6) step process to help assess our partners in their data governance structure. This process assures key constituents that the business processes and current assets are maximized.


Data Services Solution: Nintai Partners Methodology

As an example of Nintai Partners’ proprietary process, illustrated below is an example of how we might approach Phase I (Strategic Need).

Data Governance Board

Sales Sales Ops Marketing IT/IS Finance Regulatory Clinical

Corporate Strategy &

Key Objectives

What do we want to achieve from a new

data informatics strategy and organization?

Business Questions Answered

What questions need to be answered by the

proposed strategy, governance, &

structure?

Proposed Governance

& Data Model

What is the best structure and model to answer required questions and meet

key objectives?

Business Improvement

What changes in business processes can drive greater

results and improve outcomes?

Performance Review

& Actions

What tools can be utilized to measure

performance versus goals and create

executable change?


Data Services Solution: Example of New Data Requirements

Key Tools in ACO Performance Measurement

Specialty Pharmacy

Data

Emphasis on Lx Data

Patient Adherence

Pharmacy Performance

Operations Performance

Clinical Metrics

Economic Measures

Evidence Based Medicine

Emphasis on EBM

Collaborative Research

Doctor Dashboards

Doctor Impact Labeling

Research Meta Analysis

Guideline Consortiums

New Data Sets/Tools

Prescription Data

Emphasis on Rx Data

Pharma Market

Benchmarking

Forecasting

Pricing & Market Access

Sales Force Performance

Existing Data Sets/Tools

Sales Data

Emphasis on Sales Data

Hospital Dispensed

Non-Reimbursed

OTC (As Applicable)

Price Deviation

VAT Status


Data Services Solution: Case Studies of Nintai Partners’ Work

Case 1: Strategic Shift to Specialty Pharmacy (SP) Portfolio Working with a team from McKinsey, Nintai Partners developed a targeted data governance structure which met with key findings. For example, the ability to create a fully integrated message to specialty physicians about efficacy was roughly 6 times more powerful than promoting a new MoA. This meant data MUST be fully integrated internally through a stringent data governance process and included several outside data sources to demonstrate EBM performance.

Enterprise Data Warehouse

Internal Data

Physician prescription data Anonymous patient-level data

Payer data CDSC ETMS

Pre-Clinical (e.g. Dosing Safety) Phase IV Data

External Data

Research Meta Analysis Patient Adherence

Pharmacy Performance Clinical Metrics

EHR Blinded Data Guideline Measures

CMS Guidelines

Targeted Specialist

Campaigns

ACO Performance

Payer Formulary

Reimbursement


Case 2: Developing Model Data Governance Model for TBG Integration Early last year, a partner asked Nintai Partners to evaluate the best data governance model to integrate a traditionally independent therapeutic business group (TBG) structure. Utilizing an integrated, multi-department approach Nintai Partners created working groups under a Data Governance Board to review and come up with dynamic solutions addressing specific concerns.

Data Services Solution: Case Studies of Nintai Partners Work

Political/ Regulatory

Impacts

Reporting/ Insights Impact

Business Process Impact

Financial Impact

Vendor Impacts

Identification of Key Questions, Issues, and Responsibilities

Identification of Working Group Solutions

Roll Up Report to Data Governance Board and TBGs for Feedback

aco/pharma commercial data analytics service models

Healthcare

depth of data

data sets

data infrastructure

data asset

data sources step

data ownership step

data access rights step

expertise pharmaceutical